# US Swollen Knee Treatment Market

> US Swollen Knee Treatment Market Research Report By Type (Medications, Surgery) and By End User (Hospitals, Clinics) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.56%
- **2024:** $ 283.5 Million
- **2025:** $ 299.26 Million
- **2035:** $ 514.1 Million
- **Key Players:** Johnson & Johnson (US), Pfizer Inc (US), Bayer AG (DE), Novartis AG (CH), AbbVie Inc (US), GlaxoSmithKline plc (GB), Sanofi S.A. (FR), Amgen Inc (US), Merck & Co., Inc. (US)

**Report ID:** MRFR/HC/55279-HCR · **Pages:** 128 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-swollen-knee-treatment-market-57045

---

## Market Summary

## **U.S. Swollen Knee Treatment Market Overview**

As per MRFR analysis, the U.S. Swollen Knee Treatment Market Size was estimated at 268.8 (USD Million) in 2024.

The U.S. Swollen Knee Treatment Market Industry is expected to grow from 283.5(USD Million) in 2025 to 627 (USD Million) by 2035. The U.S. Swollen Knee Treatment Market CAGR (growth rate) is expected to be around 7.482% during the forecast period (2025 - 2035).

## **Key U.S. Swollen Knee Treatment Market Trends Highlighted**

The U.S. Swollen Knee Treatment Market is witnessing significant trends shaped by evolving patient needs and advancements in medical technology. One of the key market drivers is the increasing prevalence of knee-related conditions, such as osteoarthritis and rheumatoid arthritis, which are often associated with swelling. With the aging population in the U.S., a larger number of individuals are experiencing these conditions, creating a higher demand for effective treatment options.

Additionally, there is an increasing focus on non-invasive treatment methods, such as physical therapy and lifestyle modifications, which are preferred by patients looking for alternatives to surgical options.Recent trends indicate a growing interest in using biologics and regenerative medicine for swollen knee treatments. These innovative therapies, which include stem cell injections and platelet-rich plasma (PRP) treatments, are gaining traction among healthcare providers and patients alike, driven by their potential to promote healing and reduce inflammation without traditional surgical interventions.

Furthermore, telehealth services are becoming more common, allowing patients to receive consultations and monitoring from their homes, making it easier for them to manage their conditions. Opportunities in the U.S. market can be explored by focusing on personalized treatment plans that cater to an individual's specific needs and preferences.There is also potential for expanding educational initiatives aimed at both healthcare providers and patients to enhance awareness about emerging treatment options and self-management strategies. This is crucial as patient engagement and knowledge contribute significantly to treatment efficacy and overall satisfaction in their healthcare journey regarding swollen knees.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **U.S. Swollen Knee Treatment Market Drivers**

Increasing Aging Population

The U.S. Swollen Knee Treatment Industry is driven significantly by the increasing aging population in the United States. According to the United States Census Bureau, by 2030, all baby boomers will be over 65 years old, contributing to a projected total of 78 million older adults. This demographic is particularly susceptible to musculoskeletal issues, including swollen knees due to osteoarthritis and degenerative joint diseases.

Notably, the Centers for Disease Control and Prevention (CDC) reports that approximately 50% of adults aged 65 and older have doctor-diagnosed arthritis, which frequently causes knee swelling.As this population continues to grow, the demand for effective treatments and interventions in the U.S. Swollen Knee Treatment Market is expected to rise substantially, driving market growth.

Advancements in Treatment Technologies

Technological advancements in treatment options are significantly propelling the U.S. Swollen Knee Treatment Market Industry forward. Innovations in minimally invasive surgical techniques, regenerative medicine, and advanced imaging technologies have enhanced the effectiveness and safety of treatment procedures for swollen knees. For instance, the American Academy of Orthopaedic Surgeons has reported improvements in arthroscopic techniques that reduce recovery time and improve surgical outcomes.Furthermore, the effectiveness of newer biologic therapies like platelet-rich plasma injections is recognized for lowering inflammation and assisting with healing.

They are expected to advance the market as health technologies grow in popularity due to the corresponding surge in patient demand for treatments that are unobtrusive and very effective.

Growing Awareness and Early Diagnosis

There is a notable increase in awareness about swollen knee conditions and the importance of early diagnosis, which is positively influencing the U.S. Swollen Knee Treatment Market Industry. Public health campaigns initiated by organizations such as the Arthritis Foundation aim to educate individuals about the early signs and symptoms of knee swelling and arthritis.

This heightened awareness has led to more patients seeking medical consultations to obtain timely diagnoses.Data from the National Institute of Arthritis and Musculoskeletal and Skin Diseases indicates that early intervention can significantly improve treatment outcomes, which in turn fuels growth in the market as people seek access to treatment options to manage their conditions effectively.

Rise in Obesity Rates

The increasing obesity rates in the United States pose a significant driver for the U.S. Swollen Knee Treatment Market Industry. According to the CDC, more than 42% of adults in the U.S. were classified as obese in 2020, which is a notable risk factor for developing knee pathologies such as osteoarthritis.

The correlation between obesity and knee swelling is well documented, as excess body weight puts additional stress on knee joints, exacerbating inflammation and pain.This rising prevalence of obesity is likely to lead to an increased number of individuals experiencing swollen knees, subsequently driving demand for specialized treatment options within the market to address these associated complications.

## **U.S. Swollen Knee Treatment Market Segment Insights**

### **Swollen Knee Treatment Market Type Insights**

The U.S. Swollen Knee Treatment Market encompasses a diverse range of approaches categorized primarily by Type, which includes Medications and Surgery. This segmentation underlines the multifaceted nature of treatments available for conditions resulting in swollen knees, driven by various underlying causes like arthritis, injuries, or infections. Medications are critical in managing inflammation and pain, offering non-invasive options that many patients prefer. Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids often play a significant role in alleviating symptoms, thereby enhancing the quality of life for individuals affected by knee swelling.

Surgery, on the other hand, becomes vital in more severe cases where conservative treatments fail to yield satisfactory results. Surgical intervention may involve procedures like arthroscopy, total knee replacement, or corrective surgeries aimed at repairing joint damage. This segment represents a significant portion of the market due to the increasing incidence of chronic knee conditions necessitating surgical solutions as populations age in the U.S. The combination of these treatment types not only reflects advances in medical technology but also underscores the growing emphasis on personalized treatment plans for patients.

With increasing awareness among the population regarding knee health and the emergence of innovative therapies, the market is expected to evolve. Additionally, trends such as telemedicine have gained traction, offering patients easier access to consultations and treatment plans. Challenges still persist, including cost barriers and the need for insurance coverage for diverse treatments, which could impact patient choices. Nevertheless, the U.S. Swollen Knee Treatment Market presents numerous opportunities for growth, especially with ongoing Research and Development efforts aimed at improving treatment outcomes and patient satisfaction. Overall, the Type segmentation in the U.S.

Swollen Knee Treatment Market showcases a balanced approach between conservative and aggressive treatment options tailored to meet the needs of a diverse patient population dealing with knee-related ailments.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Swollen Knee Treatment Market End User Insights**

The U.S. Swollen Knee Treatment Market, specifically focusing on the End User segment, shows a diversified landscape consisting of various healthcare environments such as hospitals and clinics. Hospitals are crucial players in this market, as they often have the necessary infrastructure and specialists to manage complex cases related to swollen knees. They typically provide a wide range of treatment options, from surgical interventions to physical therapy, catering to a diverse patient demographic.

Clinics, on the other hand, focus on outpatient treatment and rehabilitation services, making them significant for managing less severe cases and ensuring quicker recovery times.The trend towards outpatient care has led to an increase in the number of specialized clinics, providing patients with tailored treatment options close to home, thus driving convenience and efficiency. Factors such as the rising aging population in the U.S. and the increasing prevalence of knee-related issues contribute to growth in these settings, positioning both hospitals and clinics as pivotal in addressing the needs of affected individuals.

Overall, the dynamics of this segment reflect a broad spectrum of care, emphasizing the need for both comprehensive hospitals and accessible clinics in the U.S. Swollen Knee Treatment Market.

**U.S. Swollen Knee Treatment Market Key Players and Competitive Insights:**

The U.S. Swollen Knee Treatment Market is characterized by a diverse competitive landscape featuring a variety of companies focused on addressing the increasingly prevalent knee-related issues. This market incorporates a range of treatment options, including pharmaceuticals, physical therapies, surgical interventions, and innovative medical devices. The growing prevalence of knee injuries, arthritis, and other conditions leading to knee swelling has spurred demand for effective treatment solutions. 

Market players are continuously striving to enhance their product offerings through research and development, strategic partnerships, and market expansion efforts. The competitive dynamics are shaped by factors such as technological advancements, regulatory frameworks, and shifts in patient preferences, all of which are critical in determining the market positioning and performance of the players involved.ConvaTec is recognized as a prominent entity within the U.S. Swollen Knee Treatment Market, leveraging its strong brand presence and established reputation.

The company focuses on providing innovative medical solutions, particularly in wound and skin care, which are critical for patients dealing with knee swelling as a result of various conditions. ConvaTec's strengths lie in its robust research and development efforts, allowing for continuous improvements and introductions of new products tailored to meet the evolving needs of healthcare providers and patients alike. 

The company’s commitment to quality and patient-centric solutions reinforces its position in the market, helping healthcare professionals achieve effective outcomes for their patients suffering from swollen knee issues. Through a network of partnerships and collaborations with healthcare institutions, ConvaTec enhances its reach and efficacy in addressing patient needs.Amgen operates as a key player in the U.S. Swollen Knee Treatment Market, particularly with its focus on biopharmaceutical products that target inflammation and pain management associated with knee conditions. The company’s portfolio includes biologic therapies that are pivotal in treating the underlying causes of knee swelling.

Amgen's strengths in the U.S. market are significantly bolstered by its robust research capabilities and ongoing investment in innovative therapies that improve patient outcomes. 

The company is active in strategic mergers and acquisitions aimed at enhancing its product range and expanding its market footprint. By aligning with emerging biotechnology firms and integrating novel treatment modalities, Amgen enhances its competitive stance within the sector. The comprehensive product offerings and focused approach to knee-related treatments position the company favorably among healthcare providers looking for effective solutions for their patients facing swollen knee issues.

**Key Companies in the U.S. Swollen Knee Treatment Market Include**

- ConvaTec
- Amgen
- Zimmer Biomet
- Medtronic
- Bayer
- AbbVie
- Molecular Partners
- MediNatura
- Heraeus Medical
- Stryker Corporation
- Acelity
- Smith & Nephew
- Johnson & Johnson
- Pfizer

**US Swollen Knee Treatment Market Industry Developments**

Recent developments in the U.S. Swollen Knee Treatment Market have focused on advancements in treatment technologies and a growing emphasis on patient-centric solutions. Companies like Zimmer Biomet and Johnson and Johnson have made significant strides in orthopedic innovations, particularly in minimally invasive surgical techniques that aim to improve recovery times and patient outcomes. 

In September 2023, Medtronic launched a new device that offers advanced imaging capabilities for knee surgeries, facilitating more accurate procedures. Furthermore, Amgen has been expanding its research into biologic treatments that target inflammation for chronic knee pain, potentially affecting millions of patients across the U.S.In terms of market dynamics, recent reports indicate a gradual rise in consumer spending on knee treatment solutions, paralleling an increase in obesity rates, which is directly contributing to knee-related issues in the U.S. population.

Additionally, in August 2023, Stryker Corporation announced the acquisition of a small biotech firm specializing in knee cartilage regeneration, which has generated interest within the market for its innovative approach. 

Growth projections for the U.S. Swollen Knee Treatment Market suggest continued investment in Research and Development from major players like AbbVie and Bayer to enhance existing product lines and introduce novel therapies.

## **Swollen Knee Treatment Market Segmentation Insights**

### **Swollen Knee Treatment Market Type Outlook**

- Medications
- Surgery

### **Swollen Knee Treatment Market End User Outlook**

- Hospitals
- Clinics

## Market Drivers

### Rising Incidence of Obesity

The swollen knee-treatment market is significantly impacted by the rising incidence of obesity in the US. Obesity is a known risk factor for various musculoskeletal disorders, including knee osteoarthritis, which often results in swelling and discomfort. The Centers for Disease Control and Prevention (CDC) reports that the obesity prevalence among adults in the US was approximately 42.4% in 2017-2018, indicating a concerning trend. This growing health crisis is likely to increase the demand for treatments aimed at alleviating knee swelling and associated pain. As healthcare professionals seek to address the obesity epidemic, they may recommend interventions that target both weight management and knee health. Therefore, the rising incidence of obesity serves as a significant driver for the swollen knee-treatment market, as it creates a larger patient population in need of effective treatment options.

### Increase in Aging Population

The swelling knee-treatment market is experiencing growth due to the increase in the aging population in the US. As individuals age, they are more susceptible to joint-related issues, including arthritis and other degenerative conditions that lead to swollen knees. According to the US Census Bureau, the population aged 65 and older is projected to reach 80 million by 2040, which represents a significant portion of the market. This demographic shift is likely to drive demand for effective treatment options, thereby expanding the swollen knee-treatment market. Healthcare providers are increasingly focusing on developing tailored treatment plans for older adults, which may include both pharmacological and non-pharmacological interventions. Consequently, the aging population is a critical driver influencing the swollen knee-treatment market, as it necessitates innovative solutions to manage knee swelling and improve quality of life.

### Growing Demand for Personalized Medicine

The swollen knee-treatment market is increasingly influenced by the growing demand for personalized medicine. Patients are seeking treatment options that are tailored to their specific needs, particularly in managing chronic conditions like knee swelling. This trend is prompting healthcare providers to adopt a more individualized approach to treatment, which may include genetic testing and biomarker analysis to determine the most effective therapies. The National Institutes of Health (NIH) has highlighted the potential of personalized medicine in improving patient outcomes, suggesting that customized treatment plans can lead to better management of knee-related issues. As the healthcare landscape shifts towards personalized care, the swollen knee-treatment market is likely to see a rise in innovative therapies that cater to the unique characteristics of each patient, thereby enhancing treatment efficacy.

### Increased Focus on Preventive Healthcare

The swollen knee-treatment market is being driven by an increased focus on preventive healthcare measures. As awareness of the importance of maintaining joint health grows, individuals are more inclined to seek preventive strategies to avoid conditions that lead to knee swelling. This shift in mindset is reflected in the rising popularity of wellness programs and educational initiatives aimed at promoting joint health. The US Department of Health and Human Services has emphasized the significance of preventive care in reducing the burden of chronic diseases, which includes conditions affecting the knees. Consequently, this focus on prevention is likely to lead to a greater demand for treatments and interventions that address early signs of knee swelling, thereby expanding the swollen knee-treatment market.

### Advancements in Rehabilitation Techniques

The swollen knee-treatment market is benefiting from advancements in rehabilitation techniques that enhance recovery outcomes for patients. Innovative approaches, such as physical therapy modalities and personalized exercise regimens, are being integrated into treatment plans for individuals experiencing knee swelling. These advancements are supported by research indicating that early intervention and tailored rehabilitation can significantly reduce recovery time and improve joint function. The American Physical Therapy Association emphasizes the importance of rehabilitation in managing knee conditions, which may lead to increased patient adherence to treatment protocols. As healthcare providers adopt these advanced rehabilitation techniques, the swollen knee-treatment market is likely to expand, offering patients more effective options for managing their symptoms and improving their overall quality of life.

## Future Outlook

The [Swollen Knee Treatment Market](https://www.marketresearchfuture.com/reports/swollen-knee-treatment-market-6406) is projected to grow at a 5.56% CAGR from 2025 to 2035, driven by increasing prevalence of knee disorders and advancements in treatment technologies.

**New opportunities:**

- Development of telehealth platforms for remote consultations and follow-ups.
- Investment in regenerative medicine techniques for knee treatment.
- Expansion of personalized treatment plans using AI-driven analytics.

By 2035, the market is expected to achieve robust growth, reflecting evolving treatment methodologies and patient needs.

## Segment Insights

### By Type: Medications (Largest) vs. Patient-controlled analgesia (Fastest-Growing)

In the US swollen knee-treatment market, Medications hold the largest share, significantly influencing treatment preferences due to their accessibility and effectiveness. Following closely are Nerve blocks and Surgery, which also play vital roles. Liposomal bupivacaine and PCA pumps constitute smaller portions of the market but are valued for specific patient needs and situations.

The growth trends within this segment are being driven by increasing patient awareness and advancements in treatment methods. Medications are evolving to provide better pain relief with fewer side effects, while PCA pumps are becoming more popular among patients seeking autonomy in pain management. The rise of outpatient and minimally invasive surgeries is fostering a shift towards more efficient treatment options, contributing to the overall growth of these therapies.

Medications (Dominant) vs. Patient-controlled analgesia (Emerging)

Medications are currently the dominant segment in the US swollen knee-treatment market, offering a variety of analgesics that cater to different patient needs. They provide accessible and effective solutions, contributing significantly to pain management strategies. In contrast, Patient-controlled analgesia (PCA) pumps are emerging as a popular option for patients who desire greater control over their analgesia. PCA pumps allow individuals to administer their pain relief, fostering patient engagement and satisfaction. Both segments cater to distinct patient demographics, with medications generally used in broader applications while PCA pumps are particularly advantageous for postoperative care. The comprehensive approach combining both methodologies enhances overall treatment efficacy.

### By End-User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the US swollen knee-treatment market, hospitals dominate the end-user segment, capturing a significant share due to their extensive resources and specialized staff. Following closely are clinics, which have been gaining traction by providing more accessible treatment options for patients, increasing their share in recent years. Ambulatory surgery centers and other facilities contribute to the market but remain smaller players in comparison to the primary segments.

Growth trends indicate a shift towards clinics as patients seek more convenient and less invasive treatment options. Hospitals, while still leading, are adapting by enhancing their outpatient services. The increasing prevalence of knee-related issues among the aging population and the rising demand for minimally invasive procedures are significant drivers of growth across all end-user segments, with clinics poised to expand rapidly.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals play a dominant role in the US swollen knee-treatment market, characterized by their comprehensive infrastructure, advanced technology, and skilled healthcare professionals dedicated to this field. They provide a full range of services, including diagnostics, surgical interventions, and post-operative care. In contrast, clinics represent an emerging segment, focusing on patient-centric care and shorter wait times. They are increasingly adopting innovative treatment protocols and technologies to meet patient demands efficiently. As healthcare continues to evolve, both hospitals and clinics are enhancing their capabilities and adapting to patients' preferences, significantly influencing the treatment landscape.

## Competitive Benchmarking

The swollen knee-treatment market exhibits a dynamic competitive landscape, characterized by a blend of innovation and strategic maneuvering among key players. Companies such as Johnson & Johnson (US), AbbVie Inc (US), and Pfizer Inc (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Johnson & Johnson (US) emphasizes innovation through its robust pipeline of orthopedic solutions, while AbbVie Inc (US) focuses on expanding its biologics portfolio to address inflammatory conditions associated with knee swelling. Pfizer Inc (US), on the other hand, is leveraging partnerships to enhance its therapeutic offerings, indicating a trend towards collaborative approaches in addressing complex medical needs.The market structure appears moderately fragmented, with a mix of established players and emerging companies vying for market share. Key tactics such as localizing manufacturing and optimizing supply chains are prevalent, allowing companies to respond swiftly to regional demands. This competitive structure fosters an environment where innovation and operational efficiency are paramount, as companies strive to differentiate themselves in a crowded marketplace.

In October  Johnson & Johnson (US) announced a strategic partnership with a leading telehealth provider to enhance patient access to knee treatment solutions. This move is significant as it aligns with the growing trend of digital health integration, potentially improving patient outcomes through remote monitoring and personalized care plans. Such initiatives may not only enhance patient engagement but also streamline the treatment process, reflecting a shift towards more patient-centric approaches in the industry.

In September  AbbVie Inc (US) launched a new clinical trial for its latest biologic therapy aimed at treating knee osteoarthritis. This strategic action underscores AbbVie's commitment to advancing treatment options for knee-related conditions, potentially positioning the company as a leader in this therapeutic area. The trial's outcomes could significantly influence market dynamics, particularly if the therapy demonstrates superior efficacy compared to existing treatments.

In August  Pfizer Inc (US) expanded its product line by acquiring a smaller biotech firm specializing in regenerative medicine for joint health. This acquisition is indicative of Pfizer's strategy to diversify its portfolio and enhance its capabilities in knee treatment. By integrating innovative technologies from the acquired firm, Pfizer may strengthen its competitive edge and address unmet medical needs in the swollen knee-treatment market.

As of November  the competitive trends in the swollen knee-treatment market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving patient care. Looking ahead, the competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative treatment modalities, and reliable supply chains. This shift may redefine how companies position themselves in the market, emphasizing the importance of adaptability and forward-thinking strategies.

## Recent News & Developments

Recent developments in the U.S. Swollen Knee Treatment Market have focused on advancements in treatment technologies and a growing emphasis on patient-centric solutions. Companies like Zimmer Biomet and Johnson and Johnson have made significant strides in orthopedic innovations, particularly in minimally invasive surgical techniques that aim to improve recovery times and patient outcomes. 

In September 2023, Medtronic launched a new device that offers advanced imaging capabilities for knee surgeries, facilitating more accurate procedures. Furthermore, Amgen has been expanding its research into biologic treatments that target inflammation for chronic knee pain, potentially affecting millions of patients across the U.S.In terms of market dynamics, recent reports indicate a gradual rise in consumer spending on knee treatment solutions, paralleling an increase in obesity rates, which is directly contributing to knee-related issues in the U.S. population.

Additionally, in August 2023, Stryker Corporation announced the acquisition of a small biotech firm specializing in knee cartilage regeneration, which has generated interest within the market for its innovative approach. 

Growth projections for the U.S. Swollen Knee Treatment Market suggest continued investment in Research and Development from major players like AbbVie and Bayer to enhance existing product lines and introduce novel therapies.

## Report Scope

| MARKET SIZE 2024 | 283.5(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 299.26(USD Million) |
| MARKET SIZE 2035 | 514.1(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.56% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Johnson & Johnson (US), Pfizer Inc (US), Bayer AG (DE), Novartis AG (CH), AbbVie Inc (US), GlaxoSmithKline plc (GB), Sanofi S.A. (FR), Amgen Inc (US), Merck & Co., Inc. (US) |
| Segments Covered | Type, End-User |
| Key Market Opportunities | Integration of telehealth services enhances access to swollen knee-treatment options for patients. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the swollen knee-treatment market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US swollen knee-treatment market in 2024?**
A: The market valuation was $283.5 Million in 2024.

**Q: What is the projected market valuation for the US swollen knee-treatment market by 2035?**
A: The projected valuation for 2035 is $514.1 Million.

**Q: What is the expected CAGR for the US swollen knee-treatment market during the forecast period 2025 - 2035?**
A: The expected CAGR is 5.56% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the US swollen knee-treatment market?**
A: Key players include Johnson & Johnson, Pfizer Inc, Bayer AG, Novartis AG, AbbVie Inc, GlaxoSmithKline plc, Sanofi S.A., Amgen Inc, and Merck & Co., Inc.

**Q: What segment had the highest valuation in the US swollen knee-treatment market in 2024?**
A: Medications had the highest valuation at $113.4 Million in 2024.

**Q: What is the projected valuation for the Patient-controlled analgesia (PCA) pumps segment by 2035?**
A: The projected valuation for the PCA pumps segment is $102.0 Million by 2035.

**Q: How does the valuation of nerve blocks compare to liposomal bupivacaine in 2024?**
A: In 2024, nerve blocks were valued at $42.5 Million, while liposomal bupivacaine was valued at $28.2 Million.

**Q: What is the expected growth in the Ambulatory Surgery Centers segment from 2024 to 2035?**
A: The Ambulatory Surgery Centers segment is expected to grow from $56.5 Million in 2024 to $102.0 Million by 2035.

**Q: Which end-user segment is projected to have the highest valuation by 2035?**
A: The Hospitals segment is projected to have the highest valuation at $207.1 Million by 2035.

**Q: What was the valuation of the Clinics segment in 2024?**
A: The Clinics segment was valued at $85.1 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-swollen-knee-treatment-market-57045*